Multiple Sclerosis

Latest News

Multiple Sclerosis Disease Activity in Patients Not Exacerbated by COVID-19

Publish Date August 15, 2022

In a retrospective study, researchers determined whether the COVID-19 pandemic and COVID-19 infection affects disease course in patients with MS.

Early Intense Treatment in Multiple Sclerosis Beneficial for Cognitive Function

Publish Date July 22, 2022

In an ongoing, longitudinal, observation study, researchers evaluated the effect of the timing of DMTs on processing speed in patients with MS.

Newer Disease-Modifying Therapies Show Promise in Pediatric-Onset Multiple Sclerosis

Publish Date July 21, 2022

In a single-center, retrospective study, researchers evaluated the effects of treatment with nDMTs compared with iDMTs in a cohort of patients with POMS.

How Did COVID-19 Affect Physical Activity in Patients With Multiple Sclerosis?

Publish Date July 18, 2022

Researchers sought to investigate the effect of the COVID-19 pandemic on physical activity in patients with MS.

Lavender Capsule Combats Fatigue in Patients With Multiple Sclerosis

Publish Date July 15, 2022

Researchers sought to determine the efficacy of a lavender capsule on reducing fatigue symptoms in patients with MS.

DMT for Multiple Sclerosis Tied to Lower Risk for In-Hospital COVID-19 Mortality

Publish Date July 11, 2022

Researchers sought to evaluate all-cause mortality at 30 days in patients with MS who were hospitalized at a VA center for COVID-19 between March 2020 and October 2021.

New or Worsening Neurologic Symptoms Post-COVID in Patients With Multiple Sclerosis

Publish Date July 1, 2022

In a retrospective review, researchers sought to investigate the neurologic outcomes in patients with MS and related disorders following COVID-19 infection.

Optimal Dose of Ponesimod for Control of Relapsing-Remitting Multiple Sclerosis

Publish Date July 1, 2022

Using an analysis of combined data, researchers evaluated the dose-response relationship of 10, 20, and 40 mg ponesimod and the long-term safety and efficacy of poneismod 20 mg in patients with relapsing-remitting MS.

Neuropathic Pain in Multiple Sclerosis: The Efficacy of 3 Neuroprotective Drugs

Publish Date June 29, 2022

The researchers sought to determine whether the use of fluoxetine, riluzole, and amiloride led to an improvement in neuropathic pain compared with placebo in patients with SPMS in a trial.

Lyvispah Now Available for Spasticity Due to MS, Other Spinal Cord Disorders

Publish Date June 28, 2022

The approval was based upon a bioavailability study in healthy adults comparing baclofen oral tablets to Lyvispah.